Literature DB >> 6225435

The mechanism of inhibition of mitochondrial oxidative phosphorylation by the nonsteroidal anti-inflammatory agent diflunisal.

P McDougall, A Markham, I Cameron, A J Sweetman.   

Abstract

The anti-inflammatory agent diflunisal was found to induce a progressive loss of respiratory control in tightly coupled rat liver mitochondria, starting at low concentrations (3.3 microM). This loss of control was accompanied by a stimulation of state 4 respiration in the presence of either succinate or glutamate plus malate as the respiratory substrate. The inhibition of state 3 respiration by oligomycin was released by diflunisal. Mitochondrial ATP hydrolysis was stimulated by diflunisal over the same concentration range that affected state 4 respiration: the stimulation was inhibited by oligomycin. It was concluded that diflunisal was acting as an uncoupler of mitochondrial oxidative phosphorylation. An identical action was found in mitochondria isolated from the livers of mice, rabbits and guinea-pigs. Potencies similar to diflunisal were found with flufenamic acid and mefenamic acid, but other anti-inflammatory agents were either less potent or inactive.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6225435     DOI: 10.1016/0006-2952(83)90024-2

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  11 in total

1.  Assessment of drug-induced mitochondrial dysfunction via altered cellular respiration and acidification measured in a 96-well platform.

Authors:  Sashi Nadanaciva; Payal Rana; Gyda C Beeson; Denise Chen; David A Ferrick; Craig C Beeson; Yvonne Will
Journal:  J Bioenerg Biomembr       Date:  2012-06-12       Impact factor: 2.945

2.  Flufenamic acid as an inducer of mitochondrial permeability transition.

Authors:  M C Jordani; A C Santos; I M Prado; S A Uyemura; C Curti
Journal:  Mol Cell Biochem       Date:  2000-07       Impact factor: 3.396

3.  Probenecid interferes with renal oxidative metabolism: a potential pitfall in its use as an inhibitor of drug transport.

Authors:  R Masereeuw; A P van Pelt; S H van Os; P H Willems; P Smits; F G Russel
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

Review 4.  Gastroprotection and nonsteroidal anti-inflammatory drugs (NSAIDS). Rationale and clinical implications.

Authors:  J Hayllar; A Macpherson; I Bjarnason
Journal:  Drug Saf       Date:  1992 Mar-Apr       Impact factor: 5.606

5.  Enantiomers of flurbiprofen can distinguish key pathophysiological steps of NSAID enteropathy in the rat.

Authors:  T Mahmud; S Somasundaram; G Sigthorsson; R J Simpson; S Rafi; R Foster; I A Tavares; A Roseth; A J Hutt; M Jacob; J Pacy; D L Scott; J M Wrigglesworth; I Bjarnason
Journal:  Gut       Date:  1998-12       Impact factor: 23.059

6.  Antimicrobial peptide-induced apoptotic death of leishmania results from calcium-de pend ent, caspase-independent mitochondrial toxicity.

Authors:  Manjusha M Kulkarni; W Robert McMaster; Wojciech Kamysz; Bradford S McGwire
Journal:  J Biol Chem       Date:  2009-04-08       Impact factor: 5.157

Review 7.  Mechanisms of NSAID-induced hepatotoxicity: focus on nimesulide.

Authors:  Urs A Boelsterli
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

8.  The involvement of lactate and calcium as mediators of the electrical and mechanical responses of the myocardium to conditions of simulated ischaemia.

Authors:  B J Northover
Journal:  Br J Pharmacol       Date:  1989-07       Impact factor: 8.739

9.  Flufenamate and Gd3+ inhibit stimulated Ca2+ influx in the epithelial cell line CFPAC-1.

Authors:  S Schumann; R Greger; J Leipziger
Journal:  Pflugers Arch       Date:  1994-10       Impact factor: 3.657

10.  Prediction of liver injury induced by chemicals in human with a multiparametric assay on isolated mouse liver mitochondria.

Authors:  Mathieu Porceddu; Nelly Buron; Célestin Roussel; Gilles Labbe; Bernard Fromenty; Annie Borgne-Sanchez
Journal:  Toxicol Sci       Date:  2012-10       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.